Following the U.S. Federal Trade Commission’s recent crackdown on “improper” patents in the FDA’s Orange Book, at least three drugmakers have made the requested changes.
Kaléo Announces Executive Appointments and New Government Business Unit
Kirkland, Quebec-based Valeo Pharma will be responsible for all commercial and medical activities for ALLERJECT in Canada for an initial period of 10 years
RICHMOND, Va.--(BUSINESS WIRE)--Kaléo, a privately held U.S. pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Naloxone Auto-injector 10 mg (NALOXONE HYDROCHLORIDE injection) indicated for the emergency treatment of people 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon, is suspected.
Marathon Asset Management has entered a definitive agreement to acquire nUS-based pharmaceutical firm Kaléo in a deal valued at $310m in cash.
Virginia pharma Kaléo has agreed to pay the United States $12.7 million to resolve accusations that the pharma caused the submission of false claims for Evzio, an injectable form of naloxone hydrochloride indicated for use to reverse opioid overdose.
Kaleo, a small and controversial company, agreed to pay $12.7 million to resolve allegations that it used gifts to persuade doctors to prescribe its high-priced Evzio opioid overdose antidote, which led U.S. health care programs to overpay for the treatment.
(Reuters) - Drugmaker Kaleo Inc will pay $12.7 million to resolve allegations it turned a blind eye to fraudulent practices at pharmacies that dispensed a pricy anti-overdose drug it sold, and provided kickbacks to doctors who prescribed it.
RICHMOND, Va., Aug. 10, 2020 /CNW/ - Kaléo, a privately held U.S. pharmaceutical company, today announced that it has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions. In addition to these public programs, the largest private insurance plans, covering more than eighteen million Canadians, now also list ALLERJECT as a covered benefit.
The Canadian health regulator said on Friday it would keep importing U.S.-based Kaleo Inc's epinephrine auto-injectors and expects adequate supply of the devices in the country over the coming months.